Table 1.

Clinical response to SU11248

PatientKIT genotype
Response to SU11248 (RECIST criteria)
Primary tumorTumor refractory to imatinib
1 (case 19)*Ins503AYIns503AY/V654AProgression after 5-wk treatment, died of disease
2 (case 10)*L576PL576P/V654AStable disease for 11 mo, still on treatment
3DelWK557-558DelWK557-558/V654AStable disease for 11 mo, still on treatment
  • Abbreviation: RECIST, Response Evaluation Criteria in Solid Tumors.

  • * Data from reference 10.